Abstract: The present invention relates to the production of anti non functional P2X7 receptor monoclonal antibodies from hybridoma cell lines.

Abstract: The invention relates to purinergic (P2X) receptors, more specifically to P2X7 receptors, the generation of antibodies and the use of antibodies and immunogens that are capable of selectively binding to a non ATP-binding P2X7 receptor but not to an ATP-binding P2X7 receptor, for the detection and treatment of disease conditions, especially cancer.

Abstract: The invention relates to the identification of a novel epitope on non-functional P2X7 receptors which are implicated in cancer. The epitope includes a region from two adjacent monomers within the three subunit receptor. Antibodies which bind to the epitope and peptides for generating the antibodies are described. The antibodies and peptides are useful in the diagnosis and treatment of cancer.

Abstract: The present invention provides antibodies that specifically bind to P2X7 receptors and distinguish between function and non-functional P2X7 receptors, pharmaceutical compositions and kits containing the antibodies, and methods of using the antibodies for the detection, diagnosis and treatment of disease conditions.

Abstract: The present invention provides antibodies that specifically bind to P2X7 receptors and distinguish between function and non-functional P2X7 receptors, pharmaceutical compositions and kits containing the antibodies, and methods of using the antibodies for the detection, diagnosis and treatment of disease conditions.

Abstract: The invention relates to purinergic (P2X) receptors, to detection of protein in extra-cellular body fluids and to antibodies for the diagnosis of a disease or condition, especially cancer.

Abstract: The present invention relates to the production of anti non functional P2X7 receptor monoclonal antibodies from hybridoma cell lines.

Abstract: A recombinant or synthetic antibody or fragment thereof, said antibody or fragment thereof including three complementarity determining regions (CDR1L or H, CDR2L or H and CDR3L or H) for forming an antigen binding site that is capable of binding to a non functional P2X7 receptor but not capable of binding to a functional P2X7 receptor.

Abstract: The present invention provides antibodies that specifically bind to P2X7 receptors and distinguish between function and non-functional P2X7 receptors, pharmaceutical compositions and kits containing the antibodies, and methods of using the antibodies for the detection, diagnosis and treatment of disease conditions.

Abstract: The present invention provides antibodies that specifically bind to P2X7 receptors and distinguish between function and non-functional P2X7 receptors, pharmaceutical compositions and kits containing the antibodies, and methods of using the antibodies for the detection, diagnosis and treatment of disease conditions.

Abstract: The present invention provides antibodies that specifically bind to P2X7 receptors and distinguish between function and non-functional P2X7 receptors, pharmaceutical compositions and kits containing the antibodies, and methods of using the antibodies for the detection, diagnosis and treatment of disease conditions.

Abstract: The present invention provides antibodies that specifically bind to P2X7 receptors and distinguish between functional and non-functional P2X7 receptors, pharmaceutical compositions and kits containing the antibodies, and methods of using the antibodies for the detection, diagnosis and treatment of disease conditions.

Abstract: The invention concerns a wide range of diseases and conditions, including cancers. The invention provides a probe for detection of such a disease or condition. The probe is able to distinguish between functional P2X7 receptors and non-functional P2X7 receptors. The probe can do this in various ways, one of which is detecting change in relation to binding of adenosine triphosphate (ATP) to the receptors.

Abstract: The invention provides a pharmaceutical composition for treatment or prevention of urinary dysfunction in a mammal. The composition includes a pharmaceutically effective amount of one or more substances capable of enabling the bladder of the mammal to mimic conditions found in advanced pregnancy. Alternately, the pharmaceutical composition has a pharmaceutically effective amount of one or more substances adapted to regulate the expression of one or more ATPases that control the supply of ATP to P2X receptors in the bladder of the mammal. In one aspect, the pharmaceutical composition may downregulate expression of subtype receptors P2X1, P2X2, P2X3 and P2X5, possibly upregulating expression of subtype receptors P2X4 and P2X6.